{"entity":{"id":"nct04821622","kind":"trial","name":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC","aka":["TALAPRO-3"],"tldr":"A phase 3 trial of Talazoparib and Enzalutamide in prostate cancer, run by Pfizer, active and no longer recruiting.","summary":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC is a phase 3 interventional study registered as NCT04821622 by Pfizer, with 599 participants enrolled, started 2021-05-12 and due to reach its primary completion in 2026-02-18. Interventions recorded: talazoparib plus enzalutamide and Placebo plus enzalutamide.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04821622","url":"https://clinicaltrials.gov/study/NCT04821622"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mhspc"],"sections":[],"technologies":["androgen-deprivation","parp-inhibitor"],"targets":[],"drugs":["talazoparib","enzalutamide"],"companies":["pfizer","astellas"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct04821622-n-engl-j-med-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04821622","phase":"3","setting":"TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER","sponsor":"Pfizer","started":"2021-05-12","startedType":"actual","enrolled":599,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04821622/","neighbours":{"cancer":[{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"androgen-deprivation","kind":"technology","name":"Androgen deprivation & AR pathway inhibitors","route":"/technologies/androgen-deprivation/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/"},{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/"}],"company":[{"id":"astellas","kind":"company","name":"Astellas","route":"/companies/astellas/"},{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}],"paper":[{"id":"paper-nct04821622-n-engl-j-med-2026","kind":"paper","name":"PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer","route":"/key-papers/paper-nct04821622-n-engl-j-med-2026/"}]}}